About Fibrosis-Inflammation Lab

Our Mission

Fibrosis-Inflammation Lab is an independent knowledge hub and CRO selection resource for researchers advancing drug discovery in fibrosis and inflammation. We deliver neutral, evidence-based coverage of preclinical models, biomarkers, signaling pathways, and clinical development landscapes — grounded exclusively in peer-reviewed literature and publicly disclosed clinical trial data — and help researchers identify the CROs best positioned to execute their studies by disease area and model.

This site is operated by an editorial team of researchers and science writers specializing in fibrosis and inflammation. Drawing on hands-on experience with liver, lung, renal, and cardiac fibrosis models and associated biomarkers, we aim to organize information at a granularity that supports real research decisions.

Coverage Areas

• •Liver fibrosis (MASH, cirrhosis, HCV-related) and models (AMLN, GAN, STAM, CCl4, etc.)
• •Pulmonary fibrosis (IPF, PPF) and bleomycin-induced models
• •Renal fibrosis (CKD, diabetic nephropathy) and UUO / adenine-induced models
• •Cardiac fibrosis (HFpEF, heart failure) and pressure overload / AngII models
• •ECM turnover markers, ELF, FibroScan, and non-invasive biomarkers
• •Key signaling pathways: TGF-β/Smad, YAP/TAZ, PDGF/FGF, Notch, Wnt

• ✓All articles are built exclusively on public sources: peer-reviewed publications, conference abstracts, publicly disclosed clinical trial data, and official regulatory materials.
• ✓We never use internal, customer, or otherwise confidential information.
• ✓Content is reviewed by domain experts to balance accuracy and readability.
• ✓Articles are reviewed periodically; significant updates are marked with an explicit updated date.
• ✓Corrections and update requests are welcome via our contact form.

We share new articles on LinkedIn and X. Subscribe to our newsletter for a curated digest delivered up to twice a month on the topics that matter for fibrosis drug discovery.